JDE Peet’s share buyback periodic update August 25, 2025

JDE Peet’s share buyback periodic update August 25, 2025 PRESS RELEASE Amsterdam, August 25, 2025 JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee company, today announced that it has repurchased 230,025 shares in the period from August 18, 2025 up to and including August 22, 2025. The shares were repurchased at an average price of EUR 26.60 per share for a total consideration of EUR 6.1 million. These repurchases were made as part of the EUR 250 million share buyback programme . The total number of shares repurchased under this programme to date is 5,477,094 ordinary s...

JDE Peet's N.V. : Entered into a definitive agreement to be acquired by Keurig Dr Pepper

JDE Peets Keurig Dr. Pepper makes € 31.85ps all cash offer for JDEP

This morning, Keurig Dr Pepper (KDP) and JDE Peet's announced that they have entered into a definitive agreement under which KDP will acquire JDE Peet's in an all cash offer. Subsequently, KDP will separate its refreshment beverage (Beverage Co) and coffee business (Global Coffee Co) into two independent companies. Under the terms of the transaction, KDP will pay JDE Peet's shareholders € 31.85ps, representing a total equity consideration of € 15.7bn. JDE Peet's will also pay the previously declared dividend of € 0.36 per share prior to the closing, with no reduction to the offer price. The of...

JDE Peets Keurig Dr. Pepper makes € 31.85ps all cash offer for JDEP

This morning, Keurig Dr Pepper (KDP) and JDE Peet's announced that they have entered into a definitive agreement under which KDP will acquire JDE Peet's in an all cash offer. Subsequently, KDP will separate its refreshment beverage (Beverage Co) and coffee business (Global Coffee Co) into two independent companies. Under the terms of the transaction, KDP will pay JDE Peet's shareholders € 31.85ps, representing a total equity consideration of € 15.7bn. JDE Peet's will also pay the previously declared dividend of € 0.36 per share prior to the closing, with no reduction to the offer price. The of...

argenx Vyvgart meets primary endpoint in snMG paving path for label expansion

argenx announced positive topline data from the pivotal ADAPT SERON study of Vyvgart in AchR-Ab seronegative gMG (snMG), showing a statistically significant improvement vs. placebo (p-value=0.0068) on the primary endpoint of MG-ADL. The positive topline results do not come as a surprise, and confirm previously reported pooled analysis showing improvements in the MG-ADL score in this gMG sub-population. The company plans to file for label expansion with the FDA, and estimates the commercial opportunity for seronegative gMG could add 11K patients on top of the 17K addressable population at launc...